Edwards Lifesciences in the news

A CVP at Edwards Lifesciences sold shares and exercised options, while the company reported strong Q2 earnings and benefited from expanded Medicare coverage for TAVR.

Edwards Lifesciences, a leader in structural heart disease therapies, received a top-tier rating upgrade following strong quarterly results and a robust balance sheet.

A Vice President at Edwards Lifesciences sold over $53,000 in company stock while the company reported strong Q2 earnings, attracted significant institutional investment, and received positive analyst ratings.

Edwards Lifesciences (EW) stock fell 3.5% today due to profit-taking, upcoming earnings, an investor event, and a recent analyst downgrade to "Hold", despite recent FDA approval for a pediatric heart valve.

UBS reaffirmed its 'Buy' rating for Edwards Lifesciences, setting a $110 price target, based on anticipated positive primary endpoint outcomes for their product and strong financial results, although secondary endpoints and future earnings revisions present some caution.

Edwards Lifesciences is hosting an earnings conference call on November 4, 2026, to discuss its third-quarter 2026 operating results.

Edwards Lifesciences obtained FDA approval for its AUTUS Size-Adjustable Valve, a pediatric surgical pulmonary valve designed to grow with children, potentially impacting its pediatric structural heart interventions.

Edwards Lifesciences commemorates two decades of providing heart valve therapies and collaborating with Singapore's healthcare and manufacturing sectors.

Edwards Lifesciences will hold an investor event with a Q&A session in San Diego on November 2, accessible via webcast.

Edwards Lifesciences' stock surpassed its two hundred day moving average, and analysts maintain a "Moderate Buy" consensus after the company reported strong Q2 earnings and increased revenue.

Barclays initiated coverage of Edwards Lifesciences with an Overweight rating and a $110 price target.

Edwards Lifesciences benefits from expanded Medicare access for heart-valve procedures, acquired Autus Valve Technologies to broaden its structural heart portfolio, and has a quarterly update scheduled.

The FDA has approved the Autus valve from Edwards Lifesciences, an expandable pediatric heart valve with synthetic polymer leaflets, allowing it to grow with children and reduce the need for multiple open-heart surgeries for congenital heart defects.

Edwards Lifesciences received FDA approval for its AUTUS valve, and while it is considered undervalued, its stock has recently declined despite strong long-term revenue projections for transcatheter therapies.

Edwards Lifesciences secured FDA approval for AUTUS, a pediatric pulmonary valve that can be surgically implanted and later expanded by catheter as a child grows.

Edwards Lifesciences secured FDA approval for its Autus valve, a groundbreaking surgical pulmonary valve for pediatric patients that expands as the child grows.

Edwards Lifesciences obtained FDA approval for a size-adjustable pediatric heart valve using synthetic leaflets, designed to grow with children and prevent multiple surgeries.

JPMorgan raised its price target for Edwards Lifesciences to $105, maintaining an "Overweight" rating.

Edwards Lifesciences secured FDA approval for its Autus pediatric heart valve, a synthetic polymer-based device that expands with a child's growth, minimizing the need for multiple open-heart surgeries.

Edwards Lifesciences' Autus Size-Adjustable Valve received FDA approval as the first surgical pulmonary valve for pediatric patients designed to grow with the child, aiming to reduce repeated surgeries.